ALLMedicine™ Dry Skin Center

May 12th, 2022 - Practice Essentials Keratosis pilaris (KP) is a genetic disorder of keratinization of hair follicles of the skin. It is an extremely common benign condition that manifests as small, rough folliculocentric keratotic papules, often described as chic...

May 10th, 2022 - Effectiveness A measure of the extent to which a specific intervention, procedure, regimen, or service when deployed in the field of routine circumstances, does it intended to do for a specific population. (Wojtezak, 2002) In this study, effective...

May 9th, 2022 - In current Dermatology practice, options for moderate acne vulgaris remain limited. Moderate acne is clinically defined as acne that has not responded to at least three months of topical therapy and is not severe enough for initial treatment with ...

Apr 21st, 2022 - Previous studies have shown the efficacy of delgocitinib (DEL) ointment, a topical Janus kinase inhibitor, against atopic dermatitis (AD). However, there is no available information regarding the efficacy of DEL ointment in maintaining remission. ...

Apr 21st, 2022 - Practice Essentials Down syndrome is by far the most common and best known chromosomal disorder in humans and the most common cause of intellectual disability. It is primarily caused by trisomy of chromosome 21 (see the image below), which gives r...

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

May 10th, 2022 - Effectiveness A measure of the extent to which a specific intervention, procedure, regimen, or service when deployed in the field of routine circumstances, does it intended to do for a specific population. (Wojtezak, 2002) In this study, effective...

May 9th, 2022 - In current Dermatology practice, options for moderate acne vulgaris remain limited. Moderate acne is clinically defined as acne that has not responded to at least three months of topical therapy and is not severe enough for initial treatment with ...

Nov 16th, 2021 - The SINATRA study is pilot study with a primary aim to explore the feasibility of the trial methodology. In addition, secondary objectives of the study will investigate if THz light is able to detect subtle differences in skin hydration and their ...

Sep 1st, 2021 - Radiodermatitis (RD), an inflammatory skin reaction, occurs in more than 90 percent of cancer patients treated with radiotherapy (RT). This is the result of the radiation causing damage to the epidermal basal skin stem cells. Based on the severity...

Jun 25th, 2021 - Every day the cells of the outer layer of skin die off, shed, and regenerate. When young, skin cells turn over quickly, but that turnover rate begins to slow with age, beginning as early as twenties. As a result, skin loses its luster and begins t...

Mar 3rd, 2022 - Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting 7% of adults and 13% of children in the United States. 1,2 Atopic dermatitis is characterized by pruritus, dry skin, and pain, all of which can negatively impact quality of li.

Jan 28th, 2022 - Patients with relapsed or corticosteroid-resistant immune thrombocytopenia (ITP) had a 33% higher response rate and 50% increase in sustained responses with all-trans retinoic acid (ATRA) plus low-dose rituximab (Rituxan), Chinese investigators re...

Jan 13th, 2022 - Adagrasib (MRTX849), both alone and in combination with cetuximab (Erbitux), demonstrated encouraging responses and disease control in heavily pretreated patients with KRAS G12C–mutated colorectal cancer (CRC), according to Jared Weiss, MD, who ad...

Nov 19th, 2021 - Mobocertinib (Exkivity), a first-in-class oral EGFR tyrosine kinase inhibitor (TKI), has been granted accelerated approval by the FDA, establishing a new treatment option for patients with metastatic non–small cell lung cancer (NSCLC) that harbors...

Nov 19th, 2021 - The FDA granted accelerated approval to the first drug to spur growth in kids with the most common form of dwarfism, the agency announced on Friday. Vosoritide (Voxzogo), a once-daily injectable treatment, is indicated for children 5 years and old...